Did you know? You can suggest edits to improve this peptide information.
Overview
What is Mazdutide?
Mazdutide (IBI362/LY3305677) is a first-in-class dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist, and a synthetic analog of oxyntomodulin. Unlike tirzepatide which targets GIP/GLP-1, mazdutide uniquely combines GLP-1's appetite suppression with glucagon's ability to stimulate thermogenesis and increase energy expenditure. Phase 3 trials (GLORY-1, GLORY-2) have demonstrated up to 20% weight loss, with recent head-to-head trials showing superiority over semaglutide for both glycemic control and weight reduction in patients with type 2 diabetes and obesity.
Key Benefits
Up to 20% body weight loss, superior glycemic control vs semaglutide, increased energy expenditure via glucagon receptor activation, improved cardiometabolic markers (BP, lipids, liver fat), once-weekly convenience
Mechanism of Action
Dual agonist of GLP-1 and glucagon receptors. GLP-1 activation: stimulates insulin release, suppresses glucagon, slows gastric emptying, reduces appetite via hypothalamic signaling. Glucagon activation: increases energy expenditure and thermogenesis, improves hepatic fat metabolism. The dual mechanism provides synergistic weight loss effects while GLP-1 counteracts glucagon's glucose-raising effects.
Molecular Information
Weight
4,563.1 Da
Length
33 amino acids
Type
Oxyntomodulin analog with fatty acid conjugation
Amino Acid Sequence:
33-amino acid linear synthetic peptide conjugated to C20 fatty diacid moiety through hydrophilic linker at Lys20
* C20 fatty diacid conjugation via hydrophilic linker for extended half-life enabling once-weekly dosing
Research Indications
Severe Obesity Management
GLORY-2 trial: 20.1% weight loss with 9mg dose over 60 weeks. 48.7% of non-diabetic participants achieved ≥20% weight reduction - approaching surgical outcomes
Metabolic Syndrome Improvement
Significant reductions in waist circumference, systolic BP (-7.57 mmHg), diastolic BP (-2.98 mmHg), triglycerides (-43%), LDL cholesterol, and uric acid
Liver Fat Reduction
Exploratory analysis from GLORY-1 showed 80.2% reduction in liver fat content, suggesting potential MASLD/MASH benefits
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Inject at any time of day, with or without food. Choose a consistent day each week. If a dose is missed, take as soon as possible within 3 days, then resume regular schedule.
Peptide Interactions
How to Reconstitute
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
Remove mazdutide vial from freezer/refrigerator and allow to reach room temperature (15-20 minutes)
Clean vial top with alcohol swab using circular motion, allow to air dry completely
Calculate appropriate reconstitution volume based on desired concentration
Draw calculated amount of bacteriostatic water into syringe, remove air bubbles
Insert needle at 45-degree angle against vial wall, NOT directly into powder
Slowly inject BAC water down the side of the vial - drop by drop to prevent foaming
Remove needle and gently swirl vial in circular motion - NEVER shake vigorously
Allow solution to sit 2-3 minutes if cloudiness persists, then swirl gently until completely clear
Final solution should be completely clear and colorless - discard if cloudy or contains particles
Label vial with reconstitution date and concentration
Store reconstituted solution at 2-8°C, use within 30 days
Quality Indicators
White to off-white lyophilized powder
Properly freeze-dried mazdutide appears as light, fluffy powder without clumping or discoloration
Clear reconstituted solution
Should be completely clear and colorless after proper reconstitution - no visible particles
Intact vial seal and labeling
Rubber stopper intact, clear mg dosage, batch numbers, and expiration dates visible
Proper storage conditions maintained
Stored at correct temperature, protected from light, no freeze-thaw cycles
Source verification
Mazdutide is primarily available from research chemical suppliers. Verify purity testing and source reputation
Clumping, discoloration, or moisture
Powder should not be clumped, yellow/brown colored, or show signs of moisture damage
Persistent cloudiness or particles
Cloudiness or visible particles after proper reconstitution indicates degradation - do not use
What to Expect
- Week 1-2: Appetite reduction, possible mild nausea, decreased portion sizes
- Week 3-4: Early weight loss begins (1-2%), improved satiety after meals
- Week 4-8: Dose escalation phase, GI symptoms typically improving, 3-5% weight loss
- Week 8-16: Steady weight loss continues (7-12%), energy expenditure effects evident
- Week 16-32: Significant weight reduction (12-17%), metabolic markers improving
- Week 32-60: Peak effects (up to 20% weight loss), sustained improvements in BP, lipids, glucose
- Note: Weight loss continues without plateau through 60 weeks in clinical trials
- Diabetic patients: Blood glucose improvements within 1-2 weeks, HbA1c reduction by week 12-20
Side Effects & Safety
- Start with lowest dose and escalate gradually every 4 weeks to minimize GI side effects
- GI symptoms (nausea, diarrhea, vomiting) are most common - typically mild-moderate and improve over time
- Increased heart rate (5-17 bpm) observed but not associated with cardiac events in trials
- Monitor for signs of pancreatitis - severe persistent abdominal pain radiating to back
- Caution with personal/family history of medullary thyroid carcinoma or MEN2 syndrome (class warning for GLP-1 agonists)
- If taking insulin or sulfonylureas, monitor blood glucose closely and reduce doses as needed
- Not recommended during pregnancy or breastfeeding - insufficient safety data
- Stay well hydrated, especially during initial weeks when GI symptoms may occur
References
GLORY-1 Phase 3 Trial - NEJM (2025)
First Phase 3 weight management trial showing clinically meaningful weight reductions with once-weekly mazdutide. Both doses achieved significant weight loss vs placebo with favorable safety profile.
View Study (opens in new tab) →GLORY-2 Phase 3 Trial (2025)
High-dose 9mg mazdutide achieved 20.1% weight loss in non-diabetic participants vs 2.8% placebo. 48.7% achieved ≥20% weight reduction. No plateau observed through week 60.
View Study (opens in new tab) →DREAMS-3 Phase 3 Trial - Head-to-Head vs Semaglutide (2025)
Mazdutide showed superiority over semaglutide on primary endpoint - 48.0% vs 21.0% achieved HbA1c <7.0% AND ≥10% weight reduction (p<0.0001). Mean HbA1c reduction -2.03% vs -1.84%.
View Study (opens in new tab) →Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia